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Introduction: Combination chemotherapy of irinotecan, a topo-
isomerase I inhibitor, and cisplatin is a standard treatment in patients
with extensive-stage small cell lung cancer (SCLC). Amrubicin, a
novel 9-aminoanthracycline, inhibits topoisomerase II. We investi-
gated a sequential triplet chemotherapy consisting of irinotecan and
cisplatin followed by amrubicin in patients with extensive-stage
SCLC.
Methods: Eligible patients were aged 20 to 70 years and had
Eastern Cooperative Oncology Group performance status of 0 or 1,
measurable lesions, and adequate organ functions. Chemotherapy
consisted of irinotecan 60 mg/m2 on days 1 and 8 plus cisplatin 60
mg/m2 on day 1 every 3 weeks for three cycles and then amrubicin
40 mg/m2 alone on days 1 to 3 every 3 weeks for three cycles.
Results: From September 2004 to September 2006, 45 patients were
enrolled, 43 were evaluable for response and survival, and 44 were
evaluable for toxicity. Twenty-eight patients (64%) completed the
full planned chemotherapy. One patient achieved complete response
and 33 had partial response for an overall response rate of 79%.
Median progression-free survival was 6.5 months. Median overall
survival was 15.4 months. Major toxicity was myelosuppression.
Grade 3 or 4 neutropenia, anemia, thrombocytopenia, and febrile
neutropenia occurred in 57%, 7%, 0%, and 7% of patients during
irinotecan/cisplatin cycles and in 91%, 27%, 9%, and 15% of
patients during amrubicin cycles, respectively.
Conclusions: The sequential triplet chemotherapy, irinotecan and
cisplatin followed by amrubicin, is an effective and well-tolerated
treatment in patients with extensive-stage SCLC. Further investiga-
tion of this treatment is warranted.
Key Words: Amrubicin, Small cell lung cancer, Sequential chemo-
therapy, Triplet chemotherapy.
(J Thorac Oncol. 2010;5: 1075–1080)
Small cell lung cancer (SCLC) accounts for approximately15% of all lung cancers. Disease extension of SCLC is
classified as limited stage or extensive stage. Limited-stage
SCLC is defined as tumor confined to the hemithorax of
origin, the mediastinum, and the supraclavicular lymph
nodes, whereas extensive-stage SCLC as tumor spread out-
side these limits. For extensive-stage SCLC, chemotherapy is
the mainstay of treatment. SCLC is highly sensitive to che-
motherapy, with a response rate of 70% to 90% in first-line
treatment. However, for most patients with extensive-stage
SCLC, the disease recurs within several months, and the
5-year survival rate is less than 1%.1 It is necessary to
develop a new treatment for this serious disease.
Irinotecan, a derivative of camptothecin, inhibits topo-
isomerase I and shows strong antitumor effect for SCLC. The
Japan Clinical Oncology Group conducted a randomized
phase III trial (JCOG 9511) comparing irinotecan plus cis-
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platin with etoposide plus cisplatin in patients with extensive-
stage SCLC.2 This trial was terminated early, because of a
highly statistically significant difference in survival between
the two arms. The median overall survival was 12.8 months
in the irinotecan/cisplatin arm and 9.4 months in the etopo-
side/cisplatin arm (p  0.002). In Japan, the combination of
irinotecan and cisplatin is recognized as a standard treatment
for extensive-stage SCLC.
Amrubicin, a novel 9-aminoanthracycline, inhibits to-
poisomerase II3 and also shows strong antitumor effect for
SCLC. The West Japan Oncology Group, formerly named the
West Japan Thoracic Oncology Group (WJTOG), conducted
a phase II study of amrubicin in previously untreated patients
with extensive-stage SCLC.4 In 35 patients treated, a re-
sponse rate of 76% and a median overall survival of 11.7
months were shown. These figures compare favorably with
standard doublet chemotherapy.
Some preclinical studies reported that a combination of
topoisomerase I and II inhibitors shows a synergistic cytotoxic-
ity.5 For SCLC, a combination of this type, irinotecan and
etoposide (a topoisomerase II inhibitor), was investigated clini-
cally and showed promising results.6,7 The similar combination
of irinotecan and amrubicin is worthwhile to investigate.
Concurrent administration of a triplet combination re-
quires dose reduction of each drug because of toxicities,
especially myelosuppression. A sequential chemotherapy,
i.e., a doublet followed by the other drug, can be used to
avoid the need for dose reduction. In addition, Norton and
Simon8 presented a theoretical model describing the possi-
bility of a sequential chemotherapy.
Therefore, we investigated a sequential triplet chemo-
therapy consisting of irinotecan and cisplatin followed by
amrubicin in patients with extensive-stage SCLC (WJTOG
0301). The purpose of this study was to evaluate the efficacy
and safety of this treatment.
PATIENTS AND METHODS
Patient Selection
Eligible patients were aged 20 to 70 years, had histo-
logically or cytologically proven SCLC, extensive-stage dis-
ease, Eastern Cooperative Oncology Group (ECOG) perfor-
mance status (PS) of 0 or 1, no prior chemotherapy, neither
palliative radiation nor surgery of 14 days, measurable le-
sions, life expectancy of at least 2 months, and adequate
organ functions (white blood cell [WBC] 4000/L, neutro-
phil 2000/L, platelet 100,000/L, hemoglobin 10
g/dL, aspartate aminotransferase [AST] and alanine amino-
transferase [ALT] 2  upper limit of normal [ULN], total
bilirubin 1.5  ULN, creatinine ULN, arterial partial
pressure of oxygen 60 mm Hg, no abnormality requiring
treatment on electrocardiogram, and left ventricular ejection
fraction on echocardiogram 60%). Patients with any of the
following conditions were excluded: symptomatic brain me-
tastases, pleural or pericardial effusion requiring drainage,
interstitial pneumonitis, active infection, watery diarrhea or
ileus, active gastroduodenal ulcer, continuous administration
of steroid or nonsteroidal anti-inflammatory drug, uncon-
trolled diabetes mellitus or angina pectoris, other active
malignancy, and pregnancy or lactation.
All patients gave written informed consent. This study
was approved by the institutional review boards at each
participating institution.
Treatment Schedule
Chemotherapy consisted of irinotecan 60 mg/m2 on
days 1 and 8 plus cisplatin 60 mg/m2 on day 1 every 3 weeks
for 3 cycles and then amrubicin 40 mg/m2 alone on days 1 to
3 every 3 weeks for three cycles. Irinotecan was administered
as a 90-minute intravenous infusion, cisplatin as a 90-minute
intravenous infusion with adequate hydration, and amrubicin
as a 5-minute intravenous injection. Prophylactic administra-
tion of granulocyte colony-stimulating factor (G-CSF) was
allowed at the discretion of the treating physician.
The minimum requirements for the administration of
irinotecan and cisplatin were as follows: WBC 3000/L,
neutrophil 1500/L, platelet 100,000/L, AST and ALT
2.5  ULN, total bilirubin 1.5  ULN, creatinine
ULN, PS of 0 to 2, body temperature37.5°C, no diarrhea,
no interstitial pneumonitis, and other nonhematological tox-
icity grade 2. The minimum requirements for administra-
tion of day-8 irinotecan were as follows: WBC 3000/L,
platelet 100,000/L, body temperature 37.5°C, no diar-
rhea, no interstitial pneumonitis, and other nonhematological
toxicity grade 2. The minimum requirements for adminis-
tration of amrubicin were as follows: WBC 3000/L,
neutrophil 1500/L, platelet 100,000/L, AST and ALT
2.5  ULN, total bilirubin 1.5  ULN, creatinine
1.5  ULN, PS of 0 to 2, body temperature 37.5°C, no
interstitial pneumonitis, and other nonhematological toxicity
grade 2.
If any of the following toxicities was observed, the
doses of irinotecan, cisplatin, and amrubicin were reduced to
50, 50, and 35 mg/m2, respectively: WBC 1000/L, febrile
neutropenia (neutrophil 1000 /L), platelet 25,000 /L,
or grade 3 nonhematologic toxicity. If creatinine ULN, the
dose of cisplatin was reduced to 50 mg/m2. If creatinine2.0
mg/dL, the administration of cisplatin was discontinued. If
grade 4 nonhematological toxicity or pneumonitis grade 2
was observed, the study treatment was stopped.
Response and Toxicity Evaluation
Before treatment, a complete medical history was ob-
tained, and physical examination was performed. The follow-
ing examinations were carried out: complete blood count
(CBC) with differential WBC count, blood chemistry, arterial
blood gas analysis, urinalysis, electrocardiography, and echo-
cardiography. Staging procedures consisted of chest radio-
graph, computed tomography (CT) of chest and upper abdo-
men, magnetic resonance imaging (MRI) or CT of brain,
bone scintigraphy, and bone marrow aspiration. During treat-
ment, CBC with differential WBC count, blood chemistry,
and chest radiograph were examined at least once a week, and
electrocardiography and CT and/or MRI for response evalu-
ation were examined once a month. After treatment, chest
radiograph was performed once a month, and CT and/or MRI
were performed every 3 months.
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Response was evaluated according to the Response
Evaluation Criteria in Solid Tumors.9 Extramural review of
eligibility and response of all patients were performed. Tox-
icity was evaluated in accordance with the Common Termi-
nology Criteria for Adverse Events, Version 3.0.10
Statistical Analysis
The primary end point of this study was response rate.
Secondary end points were progression-free survival (PFS),
overall survival, and toxicity. Survival curves were drawn
using the Kaplan-Meier method.11
Assuming that a response rate of 90% would indicate
potential usefulness, whereas a rate of 75% would be the
lower limit of interest, with   0.05 (one side) and  
0.20, 38 patients were required. Allowing for a 15% loss to
follow-up, enrollment of a total of 45 patients was planned.
RESULTS
Patient Characteristics
From September 2004 to September 2006, 45 patients
were enrolled in this study. Two patients had limited-stage
disease. One patient, who was able to receive thoracic radi-
ation, was excluded from all analyses. The other patient, who
was not able to receive thoracic radiation due to pleural
dissemination, was included in analysis of toxicity and ex-
cluded from analysis of response and survival. Therefore, 43
patients were evaluable for response and survival, and 44
were evaluable for toxicity.
Patient characteristics are shown in Table 1. The me-
dian age was 63 years, 37 patients (84%) were men, and 31
patients (70%) had PS of 1. Thirty-nine patients (89%) had
distant metastases. Frequent sites of distant metastases were
brain, liver, bone, and adrenal gland. Of five patients without
distant metastases, four had contralateral hilar lymph node
involvement and one had pleural dissemination. No patient
received prior treatment, including surgery and radiation.
Treatment Delivery
Of 44 patients, 37 patients (84%) received three cycles
irinotecan/cisplatin and 28 patients (64%) completed the full
planned chemotherapy, i.e., three cycles irinotecan/cisplatin
followed by three cycles amrubicin (Table 2). Dose reduction
of irinotecan/cisplatin and amrubicin was necessary in six and
seven patients, respectively.
Response and Survival
Of 43 patients, 1 achieved complete response and 33
had partial response, for an overall response rate of 79%
(95% confidence interval, 64–90%) (Table 3). Of the 33
partial responders, tumor shrinkage met partial response cri-
teria during an irinotecan/cisplatin cycle in 30 patients and
during an amrubicin cycle in 3. In the complete responder,
tumor disappearance was achieved during an irinotecan/cis-
platin cycle.
The survival curves are shown in Figure 1. The median
PFS was 6.5 months (95% confidence interval, 4.9–7.4
months), with a 1-year survival rate of 8%. The median
overall survival was 15.4 months (95% confidence interval,
11.7–18.0 months), with a 1-year survival rate of 61%.
Chemotherapy After Progression
(Second-Line Treatment)
Thirty-five patients received chemotherapy after pro-
gression as follows: etoposide plus carboplatin in 10 patients;
TABLE 2. Treatment Delivery (n  44)
Treatment Cycle n (%)
Irinotecan/cisplatin
Cycle 1 44 (100)
Cycle 2 40 (91)
Cycle 3 37 (84)
Amrubicin
Cycle 1 33 (75)
Cycle 2 30 (68)
Cycle 3 28 (64)
TABLE 3. Tumor Response (n  43)
n (%)
Complete response 1 (2)
Partial response 33 (77)
Stable disease 1 (2)
Progressive disease 3 (7)
Not evaluable 5 (12)
Overall response 34 (79) (95% CI, 64–90)
CI, confidence interval.
TABLE 1. Patient Characteristics (n  44)
Characteristic n (%)
Sex
Male 37 (84)
Female 7 (16)
Age (yr)
Median (range) 63 (47–70)
ECOG performance status
0 13 (30)
1 31 (70)
Distant metastases
Present 39 (89)
Absent 5 (11)
Sites of distant metastasis
Brain 10 (23)
Liver 10 (23)
Bone 10 (23)
Adrenal gland 10 (23)
Lymph node 7 (16)
Lung 6 (14)
Bone marrow 3 (7)
Other 3 (7)
Prior therapy
None 44 (100)
ECOG, Eastern Cooperative Oncology Group.
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irinotecan plus cisplatin in 6; amrubicin in 5; topotecan plus
carboplatin in 4; irinotecan plus amrubicin in 2; irinotecan in
2; and irinotecan plus etoposide, irinotecan plus carboplatin,
etoposide plus cisplatin, etoposide, topotecan, and cyclophos-
phamide plus doxorubicin plus vincristine in 1 patient each.
Toxicity
Toxicities during irinotecan/cisplatin cycles are listed
in Table 4. Of 44 patients, grade 3 or 4 leukopenia, neutro-
penia, anemia, thrombocytopenia, and febrile neutropenia
occurred in 6 (14%), 25 (57%), 3 (7%), 0 (0%), and 3 patients
(7%), respectively. G-CSF was administered in 12 patients
(27%). One patient received transfusion of red blood cell
concentrates. One patient (2%) developed grade 3 diarrhea.
Grade 3 anorexia was observed in seven patients (16%).
Toxicities during amrubicin cycles are listed in Table 5.
Of 33 patients, grade 3 or 4 leukopenia, neutropenia, anemia,
thrombocytopenia, and febrile neutropenia occurred in 15
(45%), 30 (91%), 9 (27%), 3 (9%), and 5 patients (15%),
respectively. G-CSF was administered in 20 patients (61%).
One patient received transfusion of red blood cell concen-
trates and platelet concentrates, and two other patients re-
ceived transfusion of red blood cell concentrates. Nonhema-
tological toxicity was not common. One patient (3%)
developed grade 3 pneumonitis. This patient was treated with
steroid pulse therapy and recovered soon thereafter. No
treatment-related death was observed.
DISCUSSION
We performed a phase II study of sequential triplet che-
motherapy consisting of irinotecan and cisplatin followed by
amrubicin in patients with extensive-stage SCLC and demon-
strated a response rate, median PFS, and median overall survival
of 79%, 6.5 months, and 15.4 months, respectively. The primary
end point of this study was response rate, and the expected and
the threshold rates were set 90% and 75%, respectively. The
actual response rate in this study (79%) was lower than the
expected rate but higher than the threshold. JCOG 9511 reported
a response rate, median PFS, and median overall survival of
FIGURE 1. Survival curves (n  43). A, Progression-free sur-
vival, median 6.5 months (95% confidence interval, 4.9–7.4
months), with a 1-year survival rate of 8%. B, Overall sur-
vival, median 15.4 months (95% confidence interval, 11.7–
18.0 months), with a 1-year survival rate of 61%.
TABLE 4. Toxicities During the Irinotecan/Cisplatin Cycle
(n  44)
Grade
0 1 2 3 4 >3
WBC 11 15 12 4 2 6 (14%)
Neutrophil 9 1 9 20 5 25 (57%)
Hemoglobin 3 23 15 3 0 3 (7%)
Platelet 24 19 1 0 0 0 (0%)
Febrile neutropenia 41 0 0 3 0 3 (7%)
AST/ALT 24 15 3 2 0 2 (5%)
Creatinine 35 7 2 0 0 0 (0%)
Nausea 14 14 12 4 0 4 (9%)
Vomiting 24 11 7 2 0 2 (5%)
Anorexia 11 19 7 7 0 7 (16%)
Fatigue 13 21 8 2 0 2 (5%)
Diarrhea 28 10 5 1 0 1 (2%)
Pneumonitis 44 0 0 0 0 0 (0%)
Infection 39 0 3 2 0 2 (5%)
Rash 37 6 0 1 0 1 (2%)
WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine
aminotransferase.
TABLE 5. Toxicities During the Amrubicin Cycle (n  33)
Grade
0 1 2 3 4 >3
WBC 0 3 15 12 3 15 (45%)
Neutrophil 1 0 2 18 12 30 (91%)
Hemoglobin 0 5 19 5 4 9 (27%)
Platelet 13 13 4 0 3 3 (9%)
Febrile neutropenia 28 0 0 5 0 5 (15%)
AST/ALT 25 8 0 0 0 0 (0%)
Creatinine 30 3 0 0 0 0 (0%)
Nausea 18 12 3 0 0 0 (0%)
Vomiting 31 2 0 0 0 0 (0%)
Anorexia 17 12 3 1 0 1 (3%)
Fatigue 10 18 4 1 0 1 (3%)
Diarrhea 31 1 1 0 0 0 (0%)
Pneumonitis 31 1 0 1 0 1 (3%)
Infection 29 0 2 2 0 2 (6%)
Rash 30 2 1 0 0 0 (0%)
WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine
aminotransferase.
Kobayashi et al. Journal of Thoracic Oncology • Volume 5, Number 7, July 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1078
irinotecan/cisplatin arm of 84%, 6.9 months, and 12.8 months,
respectively.2 Comparing this study with JCOG 9511, the re-
sponse rate and PFS were similar, whereas overall survival was
longer in this study. Taking the longer overall survival into
consideration, the results of this study were regarded as prom-
ising. There is a possibility that the exclusion of PS 2 patients in
this study, which were included in JCOG 9511, could have
resulted in the longer overall survival. In addition, we could not
find any specific trend that would show prolonged overall
survival among second-line treatments.
Two randomized trials that compared irinotecan/cispla-
tin with etoposide/cisplatin were conducted mainly in North
America as confirmation studies of JCOG 9511. One was
reported by Hanna et al.12 and the other was conducted by the
Southwest Oncology Group (S0124).13 Although JCOG 9511
showed survival advantage in the irinotecan/cisplatin arm
over the etoposide/cisplatin arm, these North American trials
did not show significant difference between the two arms.
Irinotecan/cisplatin is a standard chemotherapy for SCLC in
Japan, whereas etoposide/cisplatin remains standard in North
America. It was reported that the response rate, median PFS,
and median overall survival of irinotecan/cisplatin arm were
48%, 4.1 months, and 9.3 months in the trial by Hanna et al.
and 60%, 5.7 months, and 9.9 months in S0124, respectively.
This study showed better survival than the North American
trials. However, great caution is needed when comparing this
study with the North American trials. S0124 reported the
possibility that inherent genetic differences might exist be-
tween the study populations, resulting in divergent outcomes
with the same cytotoxic agents.13 A similar suggestion was
made for non-small cell lung cancer.14 Population-related
pharmacogenomics is important because the varied results for
the same treatment could be attributed to ethnic differences.
Clinical studies of amrubicin for SCLC had been per-
formed, in both first-line and second-line treatment, entirely
in Japan.15 The WJTOG study in first-line treatment reported
a response rate of 76% and median overall survival of 11.7
months.4 These figures compare favorably with standard
doublet chemotherapy. Onoda et al.16 conducted a phase II
study of amrubicin in second-line treatment. They treated 16
patients with refractory disease and 44 patients with sensitive
relapsed disease and demonstrated a response rate and me-
dian overall survival of 50% and 10.3 months in the refrac-
tory group and 52% and 11.6 months in the sensitive group,
respectively. Furthermore, the North Japan Lung Cancer
Study Group conducted a randomized phase II trial of amru-
bicin in comparison with topotecan in second-line treat-
ment.17 That trial showed a response rate and median PFS of
38% and 3.5 months for the amrubicin arm and 13% and 2.2
months for the topotecan arm, respectively. Multivariate
analysis revealed that amrubicin has more influence than
topotecan on overall survival. Amrubicin is one of the most
promising new drugs for the treatment of SCLC.
The ECOG reported a phase III trial of topotecan versus
observations after cisplatin and etoposide in extensive-stage
SCLC.18 They showed that four cycles of cisplatin/etoposide
induction therapy followed by four cycles of topotecan im-
proved PFS but failed to improve overall survival or quality
of life in extensive-stage SCLC. Results of the North Japan
Lung Cancer Study Group trial suggested that amrubicin is
more effective than topotecan for SCLC. The ECOG trial
failed to show survival benefit; however, it did show that
amrubicin, instead of topotecan, has potential to lead to better
survival in extensive-stage SCLC.
Bozcuk et al.19 reported a meta-analysis of mainte-
nance/consolidation chemotherapy in the management of
SCLC. They analyzed 14 randomized trials, encompassing
2550 patients, and concluded that maintenance/consolidation
chemotherapy improves survival in SCLC. Sequential amru-
bicin was stopped for three cycles in this study. If further
cycles of amrubicin as maintenance treatment are given, PFS
might be further prolonged.
The major toxicity of sequential amrubicin was myelo-
suppression, whereas nonhematological toxicity was not
common. In the above-mentioned WJTOG study, amrubicin
was administered at 45 mg/m2 on days 1 to 3 as mono-
therapy.4 To avoid severe myelosuppression in this study,
amrubicin was decreased to 40 mg/m2 on days 1 to 3 as
sequential chemotherapy. This study confirmed that this dose
of sequential amrubicin was feasible.
Kaneda et al.20 reported a phase I study of irinotecan
and amrubicin. They administered irinotecan on days 1 and 8
and amrubicin on days 1 to 3. They concluded that this
combination was not tolerated because of severe myelosup-
pression. Although concurrent combination of irinotecan and
amrubicin is not tolerable, this study showed that sequential
combination of these drugs is tolerable. Irinotecan and am-
rubicin were administered without G-CSF support in both this
study and the study by Kaneda et al.
In conclusion, the sequential triplet chemotherapy of
irinotecan and cisplatin followed by amrubicin is an effec-
tive and well-tolerated treatment in patients with exten-
sive-stage SCLC. Further investigation of this treatment is
warranted.
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